The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis
ObjectiveThe objective of this study was to measure the efficacy of various types and dosages of statins on C-reactive protein (CRP) levels in patients with dyslipidemia or coronary heart disease.MethodsRandomized controlled trials were searched from PubMed, Embase, Cochrane Library, OpenGray, and C...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.936817/full |
| _version_ | 1811312023762370560 |
|---|---|
| author | Jie Zhang Jie Zhang Xinyi Wang Xinyi Wang Wende Tian Wende Tian Tongxin Wang Tongxin Wang Jundi Jia Jundi Jia Runmin Lai Runmin Lai Tong Wang Tong Wang Zihao Zhang Zihao Zhang Luxia Song Luxia Song Jianqing Ju Hao Xu |
| author_facet | Jie Zhang Jie Zhang Xinyi Wang Xinyi Wang Wende Tian Wende Tian Tongxin Wang Tongxin Wang Jundi Jia Jundi Jia Runmin Lai Runmin Lai Tong Wang Tong Wang Zihao Zhang Zihao Zhang Luxia Song Luxia Song Jianqing Ju Hao Xu |
| author_sort | Jie Zhang |
| collection | DOAJ |
| description | ObjectiveThe objective of this study was to measure the efficacy of various types and dosages of statins on C-reactive protein (CRP) levels in patients with dyslipidemia or coronary heart disease.MethodsRandomized controlled trials were searched from PubMed, Embase, Cochrane Library, OpenGray, and ClinicalTrials.gov. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for data extraction and synthesis. The pairwise meta-analysis compared statins and controls using a random-effects model, and a network meta-analysis compared the types and dosages of statins using the Bayesian random-effects model. The PROSPERO registration number is CRD42021242067.ResultsThe study included 37 randomized controlled trials with 17,410 participants and 20 interventions. According to the pairwise meta-analysis, statins significantly decreased CRP levels compared to controls (weighted mean difference [WMD] = −0.97, 95% confidence interval [CI] [−1.31, −0.64], P < 0.0001). In the network meta-analysis, simvastatin 40 mg/day appeared to be the best strategy for lowering CRP (Rank P = 0.18, WMD = −4.07, 95% CI = [−6.52, −1.77]). The same was true for the high-sensitivity CRP, non-acute coronary syndrome (ACS), <12 months duration, and clear measurement subgroups. In the CRP subgroup (rank P = 0.79, WMD = −1.23, 95% CI = [−2.48, −0.08]) and ≥12-month duration subgroup (Rank P = 0.40, WMD = −2.13, 95% CI = [−4.24, −0.13]), atorvastatin 80 mg/day was most likely to be the best. There were no significant differences in the dyslipidemia and ACS subgroups (P > 0.05). Node-splitting analysis showed no significant inconsistency (P > 0.05), except for the coronary heart disease subgroup.ConclusionStatins reduced serum CRP levels in patients with dyslipidemia or coronary heart disease. Simvastatin 40 mg/day might be the most effective therapy, and atorvastatin 80 mg/day showed the best long-term effect. This study provides a reference for choosing statin therapy based on LDL-C and CRP levels. |
| first_indexed | 2024-04-13T10:29:07Z |
| format | Article |
| id | doaj.art-13a71ccd53564d9f92547cbe1f88fb2e |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-13T10:29:07Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-13a71ccd53564d9f92547cbe1f88fb2e2022-12-22T02:50:14ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-07-01910.3389/fcvm.2022.936817936817The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysisJie Zhang0Jie Zhang1Xinyi Wang2Xinyi Wang3Wende Tian4Wende Tian5Tongxin Wang6Tongxin Wang7Jundi Jia8Jundi Jia9Runmin Lai10Runmin Lai11Tong Wang12Tong Wang13Zihao Zhang14Zihao Zhang15Luxia Song16Luxia Song17Jianqing Ju18Hao Xu19National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, China Academy of Chinese Medical Sciences, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, China Academy of Chinese Medical Sciences, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, China Academy of Chinese Medical Sciences, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaObjectiveThe objective of this study was to measure the efficacy of various types and dosages of statins on C-reactive protein (CRP) levels in patients with dyslipidemia or coronary heart disease.MethodsRandomized controlled trials were searched from PubMed, Embase, Cochrane Library, OpenGray, and ClinicalTrials.gov. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for data extraction and synthesis. The pairwise meta-analysis compared statins and controls using a random-effects model, and a network meta-analysis compared the types and dosages of statins using the Bayesian random-effects model. The PROSPERO registration number is CRD42021242067.ResultsThe study included 37 randomized controlled trials with 17,410 participants and 20 interventions. According to the pairwise meta-analysis, statins significantly decreased CRP levels compared to controls (weighted mean difference [WMD] = −0.97, 95% confidence interval [CI] [−1.31, −0.64], P < 0.0001). In the network meta-analysis, simvastatin 40 mg/day appeared to be the best strategy for lowering CRP (Rank P = 0.18, WMD = −4.07, 95% CI = [−6.52, −1.77]). The same was true for the high-sensitivity CRP, non-acute coronary syndrome (ACS), <12 months duration, and clear measurement subgroups. In the CRP subgroup (rank P = 0.79, WMD = −1.23, 95% CI = [−2.48, −0.08]) and ≥12-month duration subgroup (Rank P = 0.40, WMD = −2.13, 95% CI = [−4.24, −0.13]), atorvastatin 80 mg/day was most likely to be the best. There were no significant differences in the dyslipidemia and ACS subgroups (P > 0.05). Node-splitting analysis showed no significant inconsistency (P > 0.05), except for the coronary heart disease subgroup.ConclusionStatins reduced serum CRP levels in patients with dyslipidemia or coronary heart disease. Simvastatin 40 mg/day might be the most effective therapy, and atorvastatin 80 mg/day showed the best long-term effect. This study provides a reference for choosing statin therapy based on LDL-C and CRP levels.https://www.frontiersin.org/articles/10.3389/fcvm.2022.936817/fullstatinC-reactive proteincoronary heart diseasedyslipidemianetwork meta-analysis |
| spellingShingle | Jie Zhang Jie Zhang Xinyi Wang Xinyi Wang Wende Tian Wende Tian Tongxin Wang Tongxin Wang Jundi Jia Jundi Jia Runmin Lai Runmin Lai Tong Wang Tong Wang Zihao Zhang Zihao Zhang Luxia Song Luxia Song Jianqing Ju Hao Xu The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis Frontiers in Cardiovascular Medicine statin C-reactive protein coronary heart disease dyslipidemia network meta-analysis |
| title | The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis |
| title_full | The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis |
| title_fullStr | The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis |
| title_full_unstemmed | The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis |
| title_short | The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis |
| title_sort | effect of various types and doses of statins on c reactive protein levels in patients with dyslipidemia or coronary heart disease a systematic review and network meta analysis |
| topic | statin C-reactive protein coronary heart disease dyslipidemia network meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.936817/full |
| work_keys_str_mv | AT jiezhang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jiezhang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT xinyiwang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT xinyiwang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT wendetian theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT wendetian theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongxinwang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongxinwang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jundijia theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jundijia theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT runminlai theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT runminlai theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongwang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongwang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT zihaozhang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT zihaozhang theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT luxiasong theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT luxiasong theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jianqingju theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT haoxu theeffectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jiezhang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jiezhang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT xinyiwang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT xinyiwang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT wendetian effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT wendetian effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongxinwang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongxinwang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jundijia effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jundijia effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT runminlai effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT runminlai effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongwang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT tongwang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT zihaozhang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT zihaozhang effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT luxiasong effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT luxiasong effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT jianqingju effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis AT haoxu effectofvarioustypesanddosesofstatinsoncreactiveproteinlevelsinpatientswithdyslipidemiaorcoronaryheartdiseaseasystematicreviewandnetworkmetaanalysis |